JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide
Abstract Cancer stem cells play an important role on tumor progression. Biomarkers of stem cell property and their relationship to extranodal involvement of malignant lymphocytes are undefined in diffuse large B-cell lymphoma (DLBCL). Here we showed that junctional adhesion molecule-A (JAM-A) was hi...
Guardado en:
Autores principales: | Peng-Peng Xu, Yi-Feng Sun, Ying Fang, Qi Song, Zi-Xun Yan, Yi Chen, Xu-Feng Jiang, Xiao-Chun Fei, Yan Zhao, Christophe Leboeuf, Biao Li, Chao-Fu Wang, Anne Janin, Li Wang, Wei-Li Zhao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8bcc11ed23b34a3a8a8f7e40828d481d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Jia Li, et al.
Publicado: (2021) -
CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis
por: Chen-xing Zhao, et al.
Publicado: (2021) -
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Julio Delgado, et al.
Publicado: (2021) -
Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer.
por: Liang Ma, et al.
Publicado: (2011) -
Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: M. Jules Mattes, et al.
Publicado: (2021)